Bristol, Exelixis Trials Preview Changes In Kidney Cancer Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Commenting on pivotal trial success for Bristol’s checkpoint immunotherapy Opdivo and targeted Cometriq in renal cancer, Exelixis CEO Michael Morrissey says there’s room for two new different drugs for kidney cancer, and points out that an early stage study combining them is under way.